Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176930 · ClinicalTrials.gov registry record · NA
Stem Cell Transplant for Hematological Malignancy
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 330
- Enrollment target
NCT00176930 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 330 participants.
The verdict
NCT00176930, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 330 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- RADIATION Total Body Irradiation
- BIOLOGICAL Stem Cell Transplant
- DRUG Equine ATG (ATGAM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2001-10 |
| Est. Completion | 2019-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176930
The ClinicalTrials.gov registry entry for NCT00176930 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00176930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176930 about?
NCT00176930 is a clinical study titled "Stem Cell Transplant for Hematological Malignancy". The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.
What is the current status of trial NCT00176930?
This trial is currently terminated. It is a NA study. The enrollment target is 330 participants. The study started on 2001-10. Estimated completion is 2019-12.
What interventions are being tested in trial NCT00176930?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Total Body Irradiation (RADIATION), Stem Cell Transplant (BIOLOGICAL), Equine ATG (ATGAM) (DRUG).
Who is sponsoring clinical trial NCT00176930?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.